With SFTRs first go-live phase now combined with the second in July, firms have time to get their house in order and should not be complacent, argues MarketAxess
As a veteran of the 2008 financial crisis and other industry-defining events, Consolos Sarah Nicholson shares her wisdom on how to navigate the current market upheaval, including the COVID-19 pandemic, the delayed SFTR, and the need for in-house expertise
Efficient collateral management has never been more needed in securities finance. Capco consultants discuss whats driving new demands for collateral and the impact that trend has had on the wider market
Dan Copin, group head of securities finance and repo, with Donia Rouigueb, head of sales for securities finance and repo at CACEIS, cast a spotlight on the market, their position and the views of their clients
REGIS-TRs John Kernan speaks SLT about how market participants are progressing with a matter of days left until phase one of SFTR reporting start date, 11 April 2020
Although there is plenty of work left to do before SFTRs go live in a few short weeks, Kaizen Reporting recommends a keep calm and carry on approach as the best way to avoid undue panic
IHS Markit made some major additions to its suite of services in 2019 and has begun this year with a bang in both its data analytics and fintech offerings
BNY Mellons Paul Solway discusses Asia Pacifics securities lending trends in 2020 including the impact of ESG, the fallout from GPIFs departure, and predicts how the coronavirus outbreak could influence borrower behaviour
The Options Clearing Corporations Scot Warren sits down with SLT to talk the Renaissance (no not that one), the approval of the CCPs capital management policy and the potential for changes to collateral rules
MUFG has set itself the mission of becoming the preeminent Asian bank in the global securities financing market. It has begun with a series of senior hires and plans for a brand new technology framework to reinforce its global growth plans. Drew Nicol reports
With less than four months until the first phase of SFTR comes in effect, there are some big choices to be made by those in scope. Rasa Balsyte of CME Group Regulatory Reporting discusses